Literature DB >> 7506576

Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.

W J Storkus1, H J Zeh, R D Salter, M T Lotze.   

Abstract

A novel method was developed to isolate immunogenic peptides (CD8+ T-cell epitopes) from class I complexes expressed at the cell surface of viable cells. Cells treated at pH 3.3 with citrate-phosphate buffer for periods as short as 15 s remained viable and became phenotypically class I deficient. Qualitative loss of class I determinants was verified both serologically and by the incapacity of acid-treated cells to be lysed by class I-restricted cytolytic T lymphocytes (CTLs) in contrast to non-acid-treated controls. Flow cytometric analysis of acid-treated cells suggests that class I heavy chains remain associated with the cell membrane, while the class I light chain (beta 2-microglobulin) is absent. Since the physical dissociation of beta 2-microglobulin from class I heavy chain is correlated with the release of previously class I-bound peptides, we examined acid-eluted cell-free supernatants for the presence of immunogenic peptides. Peptides were acid eluted from an influenza A strain-infected, HLA-A2+ cell line and were subsequently fractionated by reverse-phase high performance liquid chromatography (RP-HPLC). These fractionated peptides were examined for their capacity to sensitize an HLA-A2+ B cell line to lysis mediated by an influenza A matrix peptide- (Flu M1 57-68) specific, HLA-A2-restricted CTL line. A single peak of biologic activity was identified in HPLC fractions 47 and 48 derived from influenza-infected cells. These fractions contained a peptide of M(r) 968 with a sequence similar to the Flu M1 58-66 sequence GILGFVFTL. The application of this technique to other T-cell-based systems may aid in the definition of peptide epitopes relevant to viral, autoimmune, or neoplastic disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506576

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  44 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.

Authors:  Victoria L Crotzer; Nicole Glosson; Delu Zhou; Ichizo Nishino; Janice S Blum
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

3.  Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

Authors:  C Perreault; J Jutras; D C Roy; J G Filep; S Brochu
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Adapter-mediated substrate selection for endoplasmic reticulum-associated degradation.

Authors:  Kathleen Corcoran; Xiaoli Wang; Lonnie Lybarger
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

5.  Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.

Authors:  Nadine van Montfoort; Marcel G Camps; Selina Khan; Dmitri V Filippov; Jimmy J Weterings; Janice M Griffith; Hans J Geuze; Thorbald van Hall; J Sjef Verbeek; Cornelis J Melief; Ferry Ossendorp
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

Review 6.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 7.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

8.  The nature of peptides presented by an HLA class I low expression allele.

Authors:  Jan Hinrichs; Daniel Föll; Christina Bade-Döding; Trevor Huyton; Rainer Blasczyk; Britta Eiz-Vesper
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 9.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

10.  Generation of an effective anti-lung cancer vaccine by DTPP-mediated photodynamic therapy and mechanistic studies.

Authors:  Liqing Zheng; Yingxin Li; Yuxiao Cui; Huijuan Yin; Tianjun Liu; Guoqiang Yu; Feng Lv; Jichun Yang
Journal:  Lasers Med Sci       Date:  2013-02-28       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.